[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6079 followers
Created: 2025-07-23 11:23:35 UTC

Dr. Reddy’s Q1 FY26 Highlights: XX% Revenue Growth & Key Milestones 📊💊 | MCap 1,04,035.03 Cr

- Q1 FY26 revenue grew XX% YoY, with EBITDA margin at ~26.7% and RoCE ~22%.
- Net cash surplus remains strong at ₹2,922 crore.
- Announced collaboration with Alvotech for pembrolizumab (co-development, manufacturing, commercialization).
- NRT portfolio integration in Nordics completed successfully.
- USFDA inspections: Form XXX observations at X sites (CTO-5: 2, Middleburgh: 2, FTO-11: 7); Middleburg received 'VAI' status.
- Only Indian pharma with CDP Climate 'A' rating, leading in Water & Supplier Engagement.
- North America revenue: ₹3,412 Cr (+11% YoY), impacted by price erosion in Lenalidomide.
- India business grew double-digits, outperforming market with volume growth & new launches.
- Europe revenue boosted by NRT portfolio & launches: Germany (+13% YoY), UK (+10% YoY), France/Italy/Others (+30% YoY).
- PSAI segment margins compressed due to lower operating leverage.

Complete Source:

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

Preview 👇 (First X out of XX pages)

![](https://pbs.twimg.com/media/GwieKfnbsAA014b.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947980909590069493/c:line.svg)

**Related Topics**
[government spending](/topic/government-spending)
[mcap](/topic/mcap)
[quarterly earnings](/topic/quarterly-earnings)
[dr reddys](/topic/dr-reddys)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1947980909590069493)